DDIT3 and diffuse large B-cell lymphoma: Using an independent de novo DLBCL cohort uniformly treated with R-CHOP (n = 52; ref. 31), we confirmed that PRAME deletions were correlated with inferior treatment outcome (3-year DSS: PRAME CN neutral: 77.5% vs. PRAME deleted: 42.9%, P = 0.021, 3-year TTP: PRAME CN neutral: 77.5% vs. PRAME deleted: 42.9%, P = 0.021, Supplemental Figure 1).